FHIR Adverse Event Resource

Slides:



Advertisements
Similar presentations
HL7-Individual Case Safety Reporting (ICSR)
Advertisements

10/20/ The Pharmaceutical Industry and Their Influence on Pain Management in the ED J. David Haddox, DDS, MD VP, Risk Management & Health Policy.
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Adverse Events and Serious Adverse Events
Safety Reporting IN Clinical Trials
ADVERSE EVENT REPORTING
Adverse Event Reporting. Reporting Adverse Events Adverse Events (AEs) are “... any untoward medical occurrence in a subject that was not previously identified.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
Capturing and Reporting Adverse Events in Clinical Research
Director, Investigator Support & Integration Services, OCTRI
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
Module 6 Inactivated poliovirus vaccine AEFI monitoring Training for Inactivated Poliovirus Vaccine (IPV) introduction.
MONDAY, 5:00 – 5:30PM Innovative Opportunities for Patient Safety Using Electronic Health Record (EHR) Data: Perspectives from the FDA FDA to CONNECT Mitra.
Basic Pharmacovigilance Training
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Survey of Medical Informatics CS 493 – Fall 2004 November 1, 2004 V. “Juggy” Jagannathan.
New Adverse Event Reporting Policy Effective September 1, 2007.
Adverse Event Reporting.
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
© 2009 Health Level Seven ®, Inc. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven, Inc. Reg. U.S. Pat &
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
© 2012 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International.
Occurrence Reports. An occurrence report is a document used to record an event when it occurs Occurrences are reported each time an occurrence occurs.
FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.
Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
8 Medication Errors and Prevention.
Module 6 Monitoring Events Supposedly Attributable to Vaccination or Immunization (ESAVIs) Training for Inactivated Poliovirus Vaccine (IPV) introduction.
FDA Notifications and Medwatch Form Requirements Adverse Event Reporting for OTC Drugs and Dietary Supplements.
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
CLINICAL TRIALS.
REPORTING ADVERSE EVENTS AND COMPLETING THE REPORT FORM
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
BRIDG Adverse Event Sub-domain Summary
Assessing expectedness of an adverse event
8. Causality assessment:
Expedited Adverse Event Reporting Requirements
Remote Monitoring of Adverse Events
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Expedited Adverse Event Reporting Requirements
*Continue on SAE supplemental page CTT21 A if more space is required
Remote Monitoring of Adverse Events
CD-JEV AEFI monitoring
Navigating Non-Compliance
Pharmacovigilance (PV)
SERIOUS ADVERSE EVENTS REPORTING
Module 6 Rotavirus vaccine AEFI monitoring
Patient Care WG Allergy and Intolerances Project
Module 6 Rotavirus vaccine AEFI monitoring
Allergy Intolerance Resource – Model Meaning
Module 6 Rotavirus vaccine AEFI monitoring
Module 6 Rotavirus vaccine AEFI monitoring
8 Medication Errors and Prevention.
Adverse Event Reporting _____________________________
Module 6 Rotavirus vaccine AEFI monitoring
Dr Tim England TICH-2 SAE adjudicator
Patient Care WG Allergy and Intolerances Project
Adverse Event Analysis
Serious Adverse Event Reconciliation
Presentation transcript:

FHIR Adverse Event Resource HL7 San Diego WG Meeting Thursday, Q3 September 14, 2017

Agenda Review of project to date Issues for discussion Next steps Biomedical RR to Patient Care Issues for discussion Representation of adverse reaction FHIR Trackers Next steps Project management

HL7 project artifacts Project Number 1240 FHIR Resource Proposal approved by FHIR Management Group (FMG) Project artifacts PC wiki Meeting minutes and presentations Use Cases References

Project Participants FDA NIH AHRQ Practitioners/Academia Research Patient Safety National Patient Safety Foundation Pharma EHR vendors Informatics Solution Vendors

Standards Reviewed ICSR Medwatch 3500 and 3500A CFSAN CAERS BRIDG AHRQ Common Formats

Definitions The Institute for Healthcare Improvement : Unintended physical injury resulting from or contributed to by medical care (including the absence of indicated medical treatment), that requires additional monitoring, treatment, or hospitalization, or that results in death. BRIDG: Any unfavorable and unintended sign, symptom, disease, or other medical occurrence with a temporal association with the use of a medical product, procedure or other therapy, or in conjunction with a research study, regardless of causal relationship.

Use Cases (abridged) * = use case detailed Adverse Event Drug* Biologic Device* Vaccine Medical Food* Dietary Supplement* Herbals Food Cosmetics Reporter variations Healthcare Reported Patient Reported Manufacturer Reported Veterinary Reported Supply Chain Medication Reconciliation* Product Problem (device)* Product Quality (office of pharmaceutical quality) 5. Product Use Error Wrong dose* Package insert error* Wrong technique* Wrong route of administration* Wrong rate* Wrong duration* Wrong time* Expired drug* 6. Problem with use of Medication from Different Manufacturers 7. Protocol Adverse Event with IND Serious Adverse Event Unanticipated Problem* (Consider international terminology) 8. Patient Safety Incident* 9. Patient Safety Near Miss* 10. Patient Safety Unsafe Condition* * = use case detailed

Reaction Issue (old FHIR Tracker) (#11021) Discuss relationship of Adverse Reaction to Allergy Intolerance Adverse Event Currently adverse reaction part of Allergy Intolerance Resource Options Add adverse reaction data elements to AE resource Create separate adverse reaction resource Have Allergy Intolerance reference AE resource Use Condition or Observation instead Outcome - use Condition resource

Causality Use concept of “Suspect Entity” Reference other FHIR resources Substance Medication MedicationAdministration MedicationStatement Device Do we need to add others? Allows for establishing assessment, assessment method and product relatedness

FHIR Trackers GF#13302 Vocabulary issues with AdverseEvent GF#13310 Patient medical history GF#13698 AdverseEvent.suspectedEntity.instance should allow CodeableConcept Need to add “Reporter” data elements

Category Coding – GF #13302 SNOMED CT – no obvious codes MedDRA

Severity vs. Seriousness Severity of event - mild/moderate/severe Serious Adverse Event (SAE) Reporting The FDA and ICH SAE definition was used in all studies (protocols and case report forms) An SAE is defined as any adverse drug experience occurring at any dose that results in any of the following outcomes: Life-threatening Death Hospitalization/prolongation of hospitalization Congenital anomaly Persistent or significant disability/incapacity Required intervention to prevent permanent impairment/damage

GF #13310 Mostly resolved – but should medical history be changed to “supporting info”? GF#13310

SuspectEntity should be a Codeable Concept – GF #13698 Much of the time, suspect products will simply be identified by their codes.  It shouldn't be necessary to go to a separate resource to capture these details (and in some cases, systems may not even know if the code is for a device, a drug or some other substance).  Having a choice between CodeableConcept|Reference(whatever) as a type is a common convention.  So rename to instance[x] and expand the type.

Other Key Concepts References to other resources to establish medical history Reference to ResearchStudy for protocol Note references to AE resource by DetectedIssue

Next Steps Topic part of Thursday 5 PM ET meetings Project ownership